Morphea
11
1
2
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
18.2%
2 terminated out of 11 trials
71.4%
-15.1% vs benchmark
18%
2 trials in Phase 3/4
80%
4 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (11)
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
The Influence of Extracorporeal Photopheresis on Skin Sclerosis
Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
Pain Outcomes Following Intralesional Corticosteroid Injections
Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
Genetic Variants in Linear Localized Scleroderma
Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea
Molecular Effects of Topical Calcipotriene on Morphea
Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study